NeuroBo Pharmaceuticals Inc

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

BOSTON , May 12, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of Mark A. Glickman to its Board of Directors, effective as of May 11, 2023.

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

Initiation of Phase 2a Clinical Trial Expected to Occur in Q3 2023 BOSTON , May 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis (NASH), in the third quarter of 2023.

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Bright Minds Biosciences

Genprex

Heliogen

Inovio Pharmaceuticals

mCloud Technologies Corp

National CineMedia

Oncternal Therapeutics Inc

Predictive Oncology Inc

Vascular Biogenics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 10 Under $1 To Watch This Week

Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 Under $1 To Watch This Week

BOSTON , April 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The IND application supports a Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in development for the treatment of nonalcoholic steatohepatitis (NASH).

NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Company Pipeline to Focus on Cardiometabolic Disease Cash and Cash Equivalents to Fund the Company into 2024 BOSTON , March 30, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today announced financial results for the year ended December 31, 2022. "During 2022, we completed our planned shift in strategic direction with the acquisition of two very promising cardiometabolic assets that address the enormous nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes markets," stated Joe Hooker, Interim President and Chief Executive Officer of NeuroBo.

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience BOSTON , Jan. 18, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President. Mr. Hooker's appointment follows Gil Price, M.D.

NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President

Ardelyx

Digital Brands Group Inc

Silo Pharma Inc

Penny stocks to watch this week with news before 2023. The post Best Penny Stocks To Buy Before 2023?

Best Penny Stocks To Buy Before 2023? 4 To Watch Now

Faraday Future Intelligent Electric

Helbiz

Consider these factors for investing in penny stocks The post How to Manage Risk When Investing in Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Manage Risk When Investing in Penny Stocks

Blue Apron

Bed Bath & Beyond

Opendoor

PaxMedica Inc

Workhorse Group

Penny stocks to watch with higher short interest right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 7 Short Squeeze Stocks To Watch Now

Histogen

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Biotech Penny Stocks? 3 Things to Look For

CLOSES EXCLUSIVE LICENSE OF ASSETS FROM DONG-A BOSTON , Nov. 8, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced the closing of an underwritten public offering of units with gross proceeds of approximately $17.3 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by NeuroBo.  NeuroBo also announced the closing of the concurrent private placement of Series A Convertible Preferred Stock and warrants with gross proceeds of $15 million, prior to deducting placement fees and offering expenses payable by NeuroBo.

NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT

BOSTON , Nov. 4, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) (the "Company" or "NeuroBo") today announced the pricing of an underwritten public offering of units and a concurrent private placement for gross proceeds of approximately $30 million prior to deducting underwriting discounts and commissions and offering expenses payable by NeuroBo. Ladenburg Thalmann & Co. Inc., is acting as sole book-running manager and exclusive placement agent in connection with the offerings.

NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT

BOSTON , Sept. 29, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ("NeuroBo") (Nasdaq: NRBO) today announced that on September 27, 2022, NeuroBo received formal notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that NeuroBo has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market.

NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) shares are trading higher by 56.44%. Strength may be due to short interest in the stock and social media interest.

Why NeuroBo Pharmaceuticals Shares Are Up Over 50% - NeuroBo Pharmaceuticals (NASDAQ:NRBO)

FaZe Holdings Inc

Greenwich Lifesciences

Minerva Neurosciences

SurgePays

Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Leaderboard.

NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week

Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) shares are trading higher by 53.74% to $25.92 Thursday morning after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty h

NeuroBo Pharmaceuticals (NASDAQ:NRBO) – Why Neurobo Pharmaceuticals Shares Are Skyrocketing

Source: Bukhta Yurii / Shutterstock.com NeuroBo (NASDAQ: NRBO ) stock is rising higher on Thursday after the clinical-stage biotechnology company announced a new strategic partnership with Dong-A ST . NeuroBo has entered into a conditional exclusive license agreement that has it agreeing to develop and commercialize DA-1241 and DA-1726.

Why Is NeuroBo (NRBO) Stock Up 47% Today?

Exclusive License Agreement to Develop and Commercialize Phase II Clinical Stage New Chemical Entity DA-1241 for the Treatment of NASH / Type 2 Diabetes and Phase I Ready DA-1726 for the Treatment of NASH / Obesity Dong-A Commits $15 Million in Equity to Strategic Collaboration BOSTON and SEOUL, South Korea , Sept. 15, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. ("NeuroBo") (Nasdaq: NRBO), and Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies

NeuroBo Pharmaceuticals (NRBO) stock soared Tuesday after initiating a 1-for-30 reverse stock split Monday night.

NeuroBo Pharmaceuticals (NRBO) Stock Soared After A Stock Split

Source: Andrus Ciprian / Shutterstock.com NeuroBo Pharmaceuticals  (NASDAQ: NRBO ) stock is rocketing higher on Tuesday after the company underwent a reverse stock split this morning. NRBO stock went through a one-for-30 reverse stock split.

What Is Going on With NeuroBo (NRBO) Stock Today?

Mullen Automotive

Regulus Therapeutics

Here's what you need to know about trading penny stocks on September 13th The post Hot Penny Stocks to Know About Right Now? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Know About Right Now? 3 to Watch

Today's price action in NeuroBo (NASDAQ: NRBO ) is quite remarkable, to say the least. While many stocks in the market are up today, few have seen triple-digit increases like this clinical-stage biotech company.

NeuroBo (NRBO) Stock Soars 125% on Reverse Stock Split News

Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) shares are trading higher by 77.04% to $0.49 Monday morning after the company announced a 1-for-30 reverse stock split.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) – What In The World Is Going On With Neurobo Pharmaceuticals Shares?

BOSTON , Sept. 12, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company, announced today a 1-for-30 reverse split of its Common Stock, par value $0.001 ("common stock"), effective at 5:00 pm Eastern time today.

NeuroBo Pharmaceuticals Announces Reverse Stock Split

News for NeuroBo Pharmaceuticals Inc Stock (NRBO)